Your browser doesn't support javascript.
loading
Does ruxolitinib really prolong survival in individuals with myelofibrosis? The never-ending story.
Barosi, Giovanni; Gale, Robert Peter.
Affiliation
  • Barosi G; General Medicine 2, Center for the Study of Myelofibrosis, Policlinico S. Matteo Foundation, Istituto di Ricovero e Cura a Carattere Scientifico, Pavia, Italy; and.
  • Gale RP; Centre for Haematology Research, Department of Immunology and Inflammation, Imperial College London, London, United Kingdom.
Blood Adv ; 6(7): 2331-2333, 2022 04 12.
Article in En | MEDLINE | ID: mdl-35240682
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Primary Myelofibrosis Limits: Humans Language: En Journal: Blood Adv Year: 2022 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Primary Myelofibrosis Limits: Humans Language: En Journal: Blood Adv Year: 2022 Document type: Article